Core Viewpoint - The Shaanxi Provincial Drug Administration has released a plan for drug supervision and management for 2025, emphasizing the need to strengthen regulation in key varieties, links, enterprises, and regions to ensure drug quality and safety [1][2] Group 1: Regulatory Actions - Shaanxi will implement the "Qingyuan" action, focusing on drug wholesale and retail enterprises, as well as online sales, to combat illegal drug purchasing and selling channels [1] - The province aims to enhance the traceability system for drug operations, ensuring comprehensive coverage of five categories of drugs through QR code tracking [1] Group 2: Quality Supervision - Increased regulatory efforts will be directed towards vaccines, blood products, and commonly used high-value drugs, with special inspections for traditional Chinese medicine (TCM) products [1] - There will be a focus on prescription drugs and chronic disease medications, particularly in monitoring procurement channels, storage management, and information traceability [1] Group 3: Targeted Inspections - The Shaanxi Provincial Drug Administration will strengthen oversight of illegal sales of TCM formula granules and prescription drugs without proper prescriptions, as well as the absence of licensed pharmacists [2] - Special attention will be given to rural areas and small pharmacies, ensuring they have established quality management systems for drug procurement, acceptance, and storage [2] - Investigations will target issues such as substandard storage conditions and the illegal sale of TCM products, including the sale of inferior or counterfeit goods [2]